Advancing Science
The expansion in therapeutic options for inflammatory bowel disease means that more patients achieve remission and a smaller proportion require surgery than years past. The challenge now lies in identifying avenues for early intervention and tailoring therapy to optimize response, says David P. Hudesman, MD, co-director of the Inflammatory Bowel Disease Center at NYU Langone Health. Currently, he and NYU Langone colleagues are leading an expansive array of studies—from clinical trials focused on optimizing approved therapies to projects aimed at assembling a suite of medical and surgical risk prediction tools—to drive improvements in treatment along multiple fronts.
Read More
Recent Articles

Chief Quality Officer Ilseung Cho, MD, discusses the deeper meaning and impact behind NYU Langone’s top accolades for care quality and safety.

Practitioner injuries are widespread and early onset—new guidelines aim to stem the problem.

NYU Langone Health:
A Leader in Gastroenterology & GI Surgery
Ranked #5
in Gastroenterology & GI Surgery
Best in New York State
1-year post liver transplant survival
> 125
Whipple surgeries/year
Upcoming Events

This CME- and MOC-accredited course is focused on the pathophysiology, diagnosis, and treatment of complex pancreatic disease including pancreatitis, high-risk and pre-cancerous conditions, and pancreatic cancer.

Subscribe for Updates from NYU Langone Health
Sign up for Physician Focus emails for practice-changing news and perspectives from our experts at NYU Langone Health.
Select Your Interests
Copyright © 2022 NYU Langone Health, All rights reserved.
NYU Langone Health
One Park Avenue, 5th Floor
New York, NY 10016